Figure 6

(A-F) The expression of ephrinB2a (A, B) and mtmr8 (C-F) in 26 hpf embryos incubated with DMSO (A, C) or cyclopamine (B, E). (D, F) are magnification of (C, E) in the trunk vasculture. (G-H) Mtmr8 expression in 30 hpf embryos incubated with DMSO (G) or SU5416 (H). (I-J) Vegf165 expression in 26 hpf Cont-MO and Mtmr8 morphant embryos. (K) Mtmr8 expression changes revealed by Q-RT-PCR in embryos treated with different doses of SU5416 and cyclopamine (μM). (L) Vegf165 expression in 26 hpf Cont-MO and Mtmr8 morphant embryos revealed by Q-RT-PCR. (M) Statistical data of different defect phenotypes at 26 hpf in Mtmr8-MO, Mtmr8-MO+dnPKA mRNA, and Mtmr8-MO+vegf121/165 mRNA embryos.